Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, B-Cell 1Lung Neoplasms 1Erectile Dysfunction 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Sildenafil Citrate 8Tadalafil 2Surveys and Questionnaires 2Alprostadil 2udenafil 1trametinib 1sotorasib 1selpercatinib 1pembrolizumab 1osimertinib 1mirabegron 1methyl 3-mercaptopropionimidate 1lorlatinib 1dabrafenib 1cemiplimab 1brigatinib 1bicalutamide 1alpha-Tocopherol 1alectinib 1Vitamin E 1Tamoxifen 1Surgical Instruments 1Saline Solution 1Restraint, Physical 1Psychiatric Rehabilitation 1Preservation, Biological 1Pentoxifylline 1Pemetrexed 1Paclitaxel 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Erectile Dysfunction × mirabegron × Clear all
NCT03600766 2019-09-04

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Mansoura University

Phase 2 Unknown
50 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡